- Author:
Jiyeon PARK
1
;
Yeun Jun CHUNG
Author Information
- Publication Type:Review
- Keywords: alternative splicing; neoantigen; RNA editing
- MeSH: Alternative Splicing; Carcinogenesis; Humans; Immune System; Immunotherapy; Mass Screening; Peptides; RNA Editing; RNA; Sequence Analysis, RNA
- From:Genomics & Informatics 2019;17(3):e23-
- CountryRepublic of Korea
- Language:English
- Abstract: The acquisition of somatic mutations is the most common event in cancer. Neoantigens expressed from genes with mutations acquired during carcinogenesis can be tumor-specific. Since the immune system recognizes tumor-specific peptides, they are potential targets for personalized neoantigen-based immunotherapy. However, the discovery of druggable neoantigens remains challenging, suggesting that a deeper understanding of the mechanism of neoantigen generation and better strategies to identify them will be required to realize the promise of neoantigen-based immunotherapy. Alternative splicing and RNA editing events are emerging mechanisms leading to neoantigen production. In this review, we outline recent work involving the large-scale screening of neoantigens produced by alternative splicing and RNA editing. We also describe strategies to predict and validate neoantigens from RNA sequencing data.